• Depot
  • Watchlist
  • Glocke
  • Handeln

    • Therapix Biosciences Ltd News

    1,32 $ +4,76% +0,06 $
    In : 1,2345 € | 26.04.24 22:00:00 Nasdaq aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A1CY7H
    ISIN: IL0010951403
    US-Symbol: SPRC
    Typ: Aktie

    Therapix Biosciences Ltd News

    18.10.23 - PR Newswire
    Thinking about buying stock in Assembly Biosciences, Olink Holding, Nkarta, Scisparc, or Aurora Mobile?
    Thinking about buying stock in Assembly Biosciences, Olink Holding, Nkarta, Scisparc, or Aurora Mobile? PR Newswire
    07.11.22 - PR Newswire
    Thinking about buying stock in Palantir Technologies, Mullen Automotive, SciSparc, Camber Energy, or DraftKings?
    Thinking about buying stock in Palantir Technologies, Mullen Automotive, SciSparc, Camber Energy, or DraftKings? PR Newswire
    14.09.22 - PR Newswire
    Thinking about buying stock in Aditxt, Scisparc, Akerna, InMed Pharmaceuticals, or Eos Energy?
    Thinking about buying stock in Aditxt, Scisparc, Akerna, InMed Pharmaceuticals, or Eos Energy? PR Newswire
    24.08.22 - PR Newswire
    Thinking about buying stock in Scisparc, Tufin Software Technologies, Farfetch, Energy Transfer, or Minerva Neurosciences?
    Thinking about buying stock in Scisparc, Tufin Software Technologies, Farfetch, Energy Transfer, or Minerva Neurosciences? PR Newswire
    02.06.22 - ACCESSWIRE
    Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC).
    NEW YORK, NY / ACCESSWIRE / June 2, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-​the-Market for SciSparc Ltd. ...
    26.05.22 - PR Newswire
    Thinking about buying stock in Modine Manufacturing, Torrid, Kohl's, Scisparc, or Vivid Seats?
    Thinking about buying stock in Modine Manufacturing, Torrid, Kohl's, Scisparc, or Vivid Seats? PR Newswire
    17.03.22 - PR Newswire
    SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial
    SciSparc Announces Positive Results from Psychedelic-​Based Pre-​Clinical Trial Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the ...
    10.03.22 - PR Newswire
    SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
    SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases Research builds on studies with support from global experts in the field of ...
    08.03.22 - PR Newswire
    SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals
    SciSparc Enters Collaboration for the Development of Innovative Psychedelic-​Based Pharmaceuticals PR Newswire
    27.01.22 - PR Newswire
    SciSparc Presents New Leadership Lineup
    SciSparc Presents New Leadership Lineup PR Newswire
    11.01.22 - PR Newswire
    SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio
    SciSparc Exploring Psychedelics as Possible Avenue to Expand Its IP Portfolio PR Newswire
    06.01.22 - PR Newswire
    SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease
    SciSparc Announces Recruitment of First Patient for its Phase IIa Clinical Trial in Alzheimer's Disease The clinical trial will be conducted at The Israeli Alzheimer's Medical Center ...
    04.01.22 - PR Newswire
    SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders
    SciSparc Issued U.S. Patent For Its Core Technology That Treats Central Nervous Systems Disorders Patent Extends Protection for its Novel Compounds and Methods Already ...
    29.12.21 - PR Newswire
    SciSparc Provides Updates Upon Conclusion of 2021
    SciSparc Provides Updates Upon Conclusion of 2021 PR Newswire
    22.12.21 - PR Newswire
    SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today
    SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today PR Newswire
    20.12.21 - PR Newswire
    SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market
    SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market PR Newswire
    18.10.21 - PR Newswire
    SciSparc Announces the Publication of a Manuscript Describing the Tourette Syndrome Study Conducted at Yale University
    SciSparc Announces the Publication of a Manuscript Describing the Tourette Syndrome Study Conducted at Yale University The manuscript titled "A Pilot Study of a Therapeutic ...
    07.09.21 - PR Newswire
    SciSparc Awarded Three Patents For Its Novel Compounds and Methods
    SciSparc Awarded Three Patents For Its Novel Compounds and Methods Applications Approved in Australia and Japan PR Newswire
    29.06.20 - PR Newswire
    Therapix Biosciences Raises $2.6 Million in Private Placement
    Therapix Biosciences Raises $2.6 Million in Private Placement PR Newswire
    21.12.18 - PR Newswire
    Therapix Biosciences Terminates FSD Acquisition Letter of Intent
    Therapix Biosciences Terminates FSD Acquisition Letter of Intent PR Newswire

    Newssuche

    Videos

    26.04.24 +6,31%
    Technical Trading: Gold Long freitags
    Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »